$Kala制药(KALA)$ KALA Kala Pharmaceuticals risk/reward 'highly favorable,' says JPMorgan

JPMorgan analyst Christopher Neyor reiterates an Overweight rating on Kala Pharmaceuticals with a $17 price target after meeting with management. The analyst sees a "highly favorable risk/reward" for Kala, underpinned by Eysuvis, the company's lead product. The early stage launch has a "significant" market opportunity in dry eye, Neyor tells investors in a research note. With Kala shares trading at a $450M market capitalization, the shares offer an "attractive entry opportunity and valuation case," says the analyst. 


 $阿米瑞斯(AMRS)$ $Affimed(AFMD)$